Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the
angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR),
Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and
tumor cell proliferation related kinase c-Kit kinase. Anlotinib is an efficient second line
therapeutic agent in treatment for metastatic soft tissue sarcoma which has been approved in
clinical trials (ALTER-0203).Therefore , this study evaluates the safety and efficacy of
anlotinib plus epirubicin and ifosfamide treat the metastatic or advanced soft tissue sarcoma
.
Phase:
Phase 2
Details
Lead Sponsor:
Liaoning Tumor Hospital & Institute
Collaborators:
China-Japan Friendship Hospital Dalian Municipal Central Hospital Daqing Oil Field Hospital First Hospital of China Medical University Second Hospital of Jilin University The Second Affiliated Hospital of Dalian Medical University The Third Affiliated Hospital of Harbin Medical University